Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies

Radiomic Analysis of CT and MRI Scans for Predicting Treatment Response and Clinical Outcomes in Patients With Breast, Brain, Head-neck and Gynecological Malignancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05170087

Enrollment

1200

Registered

2021-12-27

Start date

2020-03-02

Completion date

2025-03-31

Last updated

2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Cancer, Breast Cancer, Gynecologic Cancer, Head and Neck Cancer

Brief summary

In this study, the investigators aim to undertake a retrospective analysis of CT and MRI scans for patients undergoing radiation treatment to develop radiomic signatures to predict treatment response and clinical outcomes.

Detailed description

Imaging in oncology has widespread application with modalities like ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) having a well-established role particularly in diagnosis, staging, assessment of treatment response, and surveillance. With the applications of radiomics in oncology, the potential of imaging as a non-invasive biomarker in treatment response, as well as genotypic characterization, has been recognized. Radiomics has the potential to tailor way towards precision oncology with the development of biomarkers that can guide personalized treatments. In this study, the investigators aim at developing CT and MRI radiomic signatures as potential biomarkers to predict treatment response and clinical outcomes for patients treated with radiation having breast, brain, head and neck, and gynecological malignancies.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Breast, head and neck, brain, and gynecological malignancies * Treated with radiation at Odette Cancer Centre between 2010 and 2019

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame	Description
Development of imaging biomarkers in predicting treatment response for breast, brain, head-neck, and gynecological malignancies	1 year	Development of imaging biomarkers in predicting treatment response
Development of imaging biomarkers in predicting clinical outcomes (survival/toxicity) for breast, brain, head-neck, and gynecological malignancies	1 year	Development of imaging biomarkers in predicting clinical outcomes (survival/toxicity)

Countries

Canada

Outcome results